Shares of Laurus Labs rose 3.79% to Rs 2,329 during Friday's trading session after the pharmaceutical company reported strong Q2FY27 results, with revenue rising 33% year-on-year (YoY) and net profit more than doubling.The strong quarterly performance was driven by sustained growth in its contract development and manufacturing organisation (CDMO) business and continued momentum in its Affordable Medicines division.In its exchange filing, Laurus Labs, a research and development-driven pharmaceutical and biotechnology company, reported revenue of Rs 2,206 crore for Q2FY27, compared with Rs 1,653 crore in the corresponding quarter last year.Net profit surged 126% YoY to Rs 441 crore from Rs 195 crore in Q2FY26, while EBITDA climbed 78% to Rs 762 crore from Rs 429 crore in the year-ago quarter.The company's EBITDA margin stood at 34.5% during the quarter, while gross margin expanded to 63% from 59.9% in Q2FY26.Live EventsCommenting on the performance, Dr Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, said the company delivered another record quarter in terms of revenue and profitability, reflecting the strength of its CDMO platform and Affordable Medicines portfolio.He highlighted the operationalisation of the company's first commercial-scale peptide manufacturing plant in Vizag, adding that significant capacity expansion was already underway to address rising demand for peptide therapeutics.